Previous Close | 0.1695 |
Open | 0.1700 |
Bid | 0.1577 x 2200 |
Ask | 0.1699 x 1100 |
Day's Range | 0.1535 - 0.1800 |
52 Week Range | 0.1300 - 1.9200 |
Volume | |
Avg. Volume | 2,053,028 |
Market Cap | 22.872M |
Beta (5Y Monthly) | 1.34 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5670 |
Earnings Date | Mar 22, 2022 - Mar 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.67 |
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.
NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq’s Listing Qualification Department, through November 14, 2022, to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's common stock continues to trade on the Nasdaq Capital Market und